4,736 results match your criteria Urticaria Chronic


Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.

J Asthma Allergy 2019 25;12:43-58. Epub 2019 Jan 25.

Respiratory, US Medical Affairs, GSK, La Jolla, CA, USA.

Purpose: Patients with severe asthma are eligible for asthma-specific biologics as add-on therapies, such as mepolizumab and omalizumab, when optimized controller therapies are unable to control their symptoms. However, few real-world data are available to describe the characteristics and associated economic burden of patients considered to be candidates for mepolizumab or omalizumab therapy.

Methods: This retrospective cohort study investigated patients with asthma (≥12 years of age) identified at the time of first mepolizumab or omalizumab administration (index date) in the MarketScan Commercial Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S189676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354698PMC
January 2019

Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review.

Int J Pediatr Otorhinolaryngol 2019 Jan 28;120:68-72. Epub 2019 Jan 28.

Division of Pediatric Rheumatology, Department of Pediatrics, IWK Health Centre, 5850/5980 University Ave, PO Box 9700, Halifax, NS, B3K 6R8, Canada. Electronic address:

Infant-onset bilateral sensorineural hearing loss is a key presenting symptom of the autoinflammatory cryopyrin-associated periodic syndrome. Other symptoms include periodic fever, cold-induced urticaria-like rash, chronic aseptic meningitis, polyarticular arthralgias, and renal AA amyloidosis. Early recognition and treatment with interleukin-1 blockade are critical for preventing disabling or fatal complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijporl.2019.01.037DOI Listing
January 2019

Does angioedema influence the quality of life in chronic spontaneous urticaria patients?

Ann Allergy Asthma Immunol 2019 Feb 12. Epub 2019 Feb 12.

Department of Internal Diseases, Allergology and Clinical Immunology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland; Department of Internal Diseases and Allergology, Institute of Medicine, University of Opole, Opole, Poland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2019.01.023DOI Listing
February 2019

Bloodletting therapy for treating patients with chronic urticaria: A systematic review and meta-analysis protocol.

Medicine (Baltimore) 2019 Feb;98(7):e14541

Beijing University of Chinese Medicine, Beijing, China.

Background: Chronic urticaria is a common disease affecting patients' quality of life, and leading to substantial burden to both patients and society. Many trials have shown that bloodletting therapy is effective in treating chronic urticaria. There are currently no systematic reviews of bloodletting therapy for chronic urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014541DOI Listing
February 2019

Intravenous immunoglobulin treatment: Where do dermatologists stand?

Authors:
Selma Emre

Dermatol Ther 2019 Feb 13:e12854. Epub 2019 Feb 13.

Department of Dermatology, Yildirim Beyazit University, Medical School, Ankara, Turkey.

Intravenous immunoglobulins are therapeutic products, comprising polyclonal IgGs, which are obtained from human plasma pool of healthy blood donors. Despite the lack of FDA approval, the experience of using IVIG in various dermatological diseases increases day by day and exciting results are reported. However, experience with the use of IVIG in dermatological indications are mostly case reports whereas randomized, controlled, double-blind, multicentric studies have not been performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12854DOI Listing
February 2019

The role of patient-reported outcomes in the management of chronic spontaneous urticaria.

Authors:
Kate Hopkinson

Br J Nurs 2019 Feb;28(3):144-150

Allergy Nurse Specialist, Department of Clinical Immunology and Allergy, Nottingham University Hospitals NHS Trust.

Chronic spontaneous urticaria (CSU) is a debilitating condition that can substantially affect patients' quality of life (QoL), mental health and ability to perform daily tasks. International guidelines on the management of CSU, jointly developed by the European Academy of Allergy and Clinical Immunology (EAACI), Global Allergy and Asthma European Network (GALEN), European Dermatology Forum (EDF) and World Allergy Organization (WAO), recommend a treat-to-target strategy until symptom control or remission is achieved. This may mean stepping up or down in the treatment algorithm according to the course of CSU and re-evaluating the need for continued/alternative drug treatment. Read More

View Article

Download full-text PDF

Source
http://www.magonlinelibrary.com/doi/10.12968/bjon.2019.28.3.
Publisher Site
http://dx.doi.org/10.12968/bjon.2019.28.3.144DOI Listing
February 2019
2 Reads

The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience.

Open Access Maced J Med Sci 2019 Jan 28;7(2):259-263. Epub 2019 Jan 28.

University of Rome G. Marconi, Rome, Italy.

Background: Chronic urticaria, a mast cell-driven condition, is common, debilitating and hard to treat. H1-antihistamines are the first line treatment of chronic urticaria, but often patients do not get satisfactory relief with the recommended dose. European guidelines recommend increased antihistamine doses up to four-fold. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364734PMC
January 2019
1 Read

Sense of coherence in selected allergic diseases.

Wiad Lek 2018 ;71(9):1774-1776

Department Of Psychiatry In Tarnowskie Gory, School Of Medicine With The Division Of Dentistry In Zabrze, Medical University Of Silesia, Zabrze, Polska.

According to "holistic" model of physician's approach to the patient, physical, psychological and social aspects should be taken into account when we assess disease and effects of diagnostics and treatment. Those attributes form health related quality of life. Patient's disposition to disease depends on many psychological factors, among them sense of coherence (SOC). Read More

View Article

Download full-text PDF

Source
January 2018
1 Read

GSK2646264, a spleen tyrosine kinase inhibitor attenuates the release of histamine in ex vivo human skin.

Br J Pharmacol 2019 Feb 8. Epub 2019 Feb 8.

Respiratory TAU, GSK, Gunnels Wood Rd, Stevenage.

Background And Purpose: Chronic Spontaneous Urticaria presents as a heterogeneous syndrome characterised by wheals, angioedema or both for greater than six weeks. Spleen tyrosine kinase (SYK) mediates allergen-induced mast cell degranulation via the IgE signalling pathway, a central component of wheal formation and inflammation. In this study, we demonstrate that perfused or topically administered GSK2646264 dose dependently attenuates IgE-mediated histamine release from mast cells in an ex vivo human skin model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.14610DOI Listing
February 2019
1 Read

The response to treatment in chronic spontaneous urticaria depends on how it is measured.

J Allergy Clin Immunol Pract 2019 Feb 4. Epub 2019 Feb 4.

Dept. of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.048DOI Listing
February 2019
1 Read

[Chilean guidelines for chronic urticaria].

Rev Med Chil 2018 Nov;146(11):1334-1342

Departamento de Dermatología, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872018001101334DOI Listing
November 2018
1 Read

Omalizumab for atopic dermatitis: evidence for and against its use.

G Ital Dermatol Venereol 2019 Feb 4. Epub 2019 Feb 4.

Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

Introduction: Omalizumab, has been used for almost two decades, mainly in allergic asthma and chronic spontaneous urticaria for which it is highly beneficial. Smaller studies have evaluated the effects of omalizumab in atopic dermatitis (AD). Current treatments options, such as cyclosporine and azathioprine have limited effect on AD and numerous side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06302-8DOI Listing
February 2019
1 Read

Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine.

G Ital Dermatol Venereol 2019 Feb 4. Epub 2019 Feb 4.

Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain -

The second-generation H1-antihistamines (sgAH) are the first-line symptomatic treatment of patients with chronic spontaneous urticaria (CSU). Up to 50% of the patients will not respond to licensed doses of sgAH. According to the guidelines, the dose of sgAH may be increased up to 4 times the conventional dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06274-6DOI Listing
February 2019
1 Read

H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.

J Allergy Clin Immunol Pract 2019 Jan 29. Epub 2019 Jan 29.

Department of Dermatology and Allergy, Allergie-Centrum Charité, Charité -Universitätsmedizin Berlin, Berlin, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.030DOI Listing
January 2019
1 Read

Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study).

Health Qual Life Outcomes 2019 Jan 31;17(1):23. Epub 2019 Jan 31.

Allergy Unit, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Background: The daily diary Urticaria Activity Score (UAS) and its weekly score (UAS7) are widely used to assess signs and symptoms in patients with chronic spontaneous urticaria (CSU). The objective of this study was to assess the psychometric properties of a Spanish version of the once-daily UAS.

Methods: Observational study in patients ≥18 years old receiving usual care for CSU (daily or almost daily occurrence of generalized hives or angioedema for ≥6 weeks). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12955-019-1087-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357477PMC
January 2019
1 Read

The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study).

Eur J Dermatol 2018 Dec;28(6):795-802

Hospices civils de Lyon, Claude-Bernard University, Lyon, France.

Data on the clinical burden of chronic spontaneous urticaria (CSU) and economic consequences are lacking in France. To characterize the clinical and economic burden of CSU in symptomatic patients despite treatment by analysing data of French patients from the ASSURE-CSU study. ASSURE-CSU was an international observational study that included CSU patients with symptoms that lasted for 12 months or more despite treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3446DOI Listing
December 2018
1 Read

New Insights into the Utility of Omalizumab.

J Allergy Clin Immunol 2019 Jan 25. Epub 2019 Jan 25.

Department of Internal Medicine, Division of Allergy and Immunology at the Morsani College of Medicine of the University of South Florida in Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2019.01.016DOI Listing
January 2019
1 Read

Headache deteriorates the quality of life in children with chronic spontaneous urticaria.

Allergol Immunopathol (Madr) 2019 Jan 24. Epub 2019 Jan 24.

Akdeniz University, Department of Pediatric Allergy and Immunolgy, Antalya, Turkey.

Background: Quality of life, which is impaired in patients with chronic spontaneous urticaria (CSU), is influenced by comorbid mental disorders. Headaches could be another comorbid mental disorder that affects quality of life in children with CSU.

Objectives: To investigate the effect of headaches on urticaria symptoms, disease activity and quality of life in children with CSU. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aller.2018.09.002DOI Listing
January 2019
1 Read

Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.

J Allergy Clin Immunol Pract 2019 Jan 25. Epub 2019 Jan 25.

Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Electronic address:

Background: The high-affinity IgE receptor (FcεRI) expression on effector cells has been poorly characterized in patients with chronic urticaria (CU) to date.

Objectives: To investigate the FcεRI expression on blood basophils in a large cohort of patients with CU and its potential relationship with relevant features of the disease.

Methods: Basophil FcεRI expression was measured by flow cytometry in 287 patients with CU (192 with chronic spontaneous urticaria and 95 with chronic inducible urticaria) at their initial evaluation in our department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.026DOI Listing
January 2019
2 Reads

Advances in the pathogenesis representing definite outcomes in chronic urticaria.

Curr Opin Allergy Clin Immunol 2019 Jan 22. Epub 2019 Jan 22.

Universidad de Antioquia, Colombia.

Purpose Of Review: We reviewed in this article, the recent advances in CSU physiopathology and potential clinical and laboratory biomarkers in CSU.

Recent Findings: In addition to the central role of mast cells in urticaria physiopathology, increased interest in basophils has arisen. Recent data corroborate the autoimmunity pathway as one of the main pathways in mast cell activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ACI.0000000000000519DOI Listing
January 2019
3 Reads

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report.

Allergy Asthma Clin Immunol 2019 17;15. Epub 2019 Jan 17.

3Department of Medicine, Western University, London, ON Canada.

Background: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been described; however, their relationship to the drug remains uncertain, and the frequency is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13223-019-0319-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337756PMC
January 2019
1 Read

[Experience in the treatment of difficult diseases by technical combination of acupuncture].

Authors:
Lai-Xi Ji

Zhongguo Zhen Jiu 2019 Jan;39(1):73-6

Shanxi University of CM, Taiyuan 030619, China.

The technical combination of acupuncture is a combination therapy based on the purpose of improving clinical efficacy. After years of clinical practice, the author has gradually summarized the dominant disease spectrum of combination therapy, especially for the treatment of difficult diseases such as male and dermatological. In the treatment of chronic prostatitis, the combination of acupuncture at "Zhibian (BL 54) through Shuidao (ST 28) therapy" is adopted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13703/j.0255-2930.2019.01.016DOI Listing
January 2019
1 Read

Cytokines and soluble receptors of the interleukin-1 family in Schnitzler syndrome.

Scand J Rheumatol 2019 Jan 22:1-4. Epub 2019 Jan 22.

b Institute of Protein Biochemistry , National Research Council , Naples , Italy.

Objectives: Schnitzler syndrome (SchS) is an autoinflammatory disorder characterized by chronic urticaria, fever, and monoclonal gammopathy. The success of interleukin-1 (IL-1) blocking therapies suggests a crucial role for IL-1 in disease induction. The aim of this study is to perform a comprehensive analysis of IL-1 family cytokines and soluble receptors in a group of SchS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03009742.2018.1550210DOI Listing
January 2019
1 Read

Efficacy of autologous whole blood or serum therapy for chronic spontaneous urticaria: A systematic review and meta-analysis.

J Dermatolog Treat 2019 Jan 21:1-28. Epub 2019 Jan 21.

a Department of Dermatology , Taipei Medical University Hospital , Taipei , Taiwan.

Background: Chronic spontaneous urticaria (CSU) is chronic wheals without identifiable exogenous stimuli. Autologous whole blood (AWB) injection and autologous serum therapy (AST) are alternative therapies for CSU that induce tolerance to circulating histamine-releasing factors.

Objective: We elucidated currently available evidence for the efficacy and safety of AWB therapy and AST for CSU. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1
Publisher Site
http://dx.doi.org/10.1080/09546634.2019.1572863DOI Listing
January 2019
8 Reads

Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.

Asian Pac J Allergy Immunol 2019 Jan 13. Epub 2019 Jan 13.

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Urticarial vasculitis (UV) is a rare form of cutaneous leukocytoclastic vasculitis with persistent urticarial lesions. UV may be severe and refractory to standard treatment including antihistamines, anti-inflammatories, antimalarials, corticosteroids and immunosuppressants. Omalizumab, an anti-IgE antibody, is approved for chronic spontaneous urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12932/AP-050918-0402DOI Listing
January 2019
5 Reads

Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.

Dermatol Ther 2019 Jan 18:e12829. Epub 2019 Jan 18.

Dermatology and Venereology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain.

Bullous pemphigoid (BP) is an acquired autoimmune bullous disease characterized by autoantibodies against the hemidesmosomal proteins found in the basal keratinocytes of the basement membrane zone (BMZ): a 180 kDa protein (type XVII collagen) mainly and the 230 kDa antigen. There is such evidence that the antibodies against the BMZ components are not only of IgG type, but also this bullous disease may have IgE antibodies directed to the BMZ that contribute to the pathogenesis of the disorder. IgE is not only thought to contribute to the pathogenesis of BP, it has also been suggested that eosinophils play a role in the development of the first signs associated with BP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12829DOI Listing
January 2019
2 Reads

[Angioedema prophylaxis].

Authors:
V Zampeli M Magerl

Hautarzt 2019 Feb;70(2):107-115

Klinik für Dermatologie, Venerologie und Allergologie, Allergie-Centrum-Charité/ECARF, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.

Angioedema is a spontaneous, edematous swelling of the deep layers of the skin or mucous membrane. Angioedema in the respiratory tract is potentially life-threatening. The classification of angioedema into mast-cell-mediated (e. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00105-018-4345-9
Publisher Site
http://dx.doi.org/10.1007/s00105-018-4345-9DOI Listing
February 2019
5 Reads

Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.

J Allergy Clin Immunol Pract 2019 Jan 15. Epub 2019 Jan 15.

Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain; RETIC de Asma, Reacciones adversas y Alérgicas (ARADYAL), Madrid, Spain. Electronic address:

Background: Cholinergic urticaria (UCOL) is a highly disabling inducible urticaria triggered by an increase in core body temperature.

Objective: To explore the safety and efficacy of omalizumab in controlling UCOL.

Methods: We conducted a multicenter randomized mixed double-blind and open-label (first 4 months blinded followed by 8 months open-label) placebo-controlled clinical trial in 22 patients suffering from UCOL who were unresponsive to a double dose of antihistamines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.12.025DOI Listing
January 2019
5 Reads

Complexities in analyzing human basophil responses to autoantibodies to IgE or FcεRI.

Authors:
Stephen J Galli

J Allergy Clin Immunol 2019 Jan 14. Epub 2019 Jan 14.

Department of Pathology, Stanford University School of Medicine, Stanford, Calif; Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif; Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, Calif. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2018.12.998DOI Listing
January 2019
4 Reads

Determination the Subtypes of Blastocystis sp. and Evaluate the Effect of These Subtypes on Pathogenicity.

Acta Parasitol 2019 Jan 16. Epub 2019 Jan 16.

Department of Genetics, Faculty of Veterinary, Dicle University, Diyarbakir, Turkey.

Purpose: The present study aimed to determine the frequency of subtypes of Blastocystis sp. in the immunosuppressed individuals, in patients with chronic urticaria, and in patients with GIS complaints to investigate the difference of Blastocystis sp. subtype distribution between patient and control groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/s11686-018-00002-yDOI Listing
January 2019
1 Read

Omalizumab in children with severe allergic disease: a case series.

Ital J Pediatr 2019 Jan 14;45(1):13. Epub 2019 Jan 14.

Department of Pediatrics, Allergy Unit, University of Messina, Via Consolare Valeria-Gazzi, 98124, Messina, Italy.

Background: Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13052-019-0602-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332555PMC
January 2019
2 Reads
1.236 Impact Factor

Another look at cyclosporine for treating antihistamine-resistant chronic spontaneous urticaria.

Authors:
Miles Weinberger

Ann Allergy Asthma Immunol 2019 Jan 12. Epub 2019 Jan 12.

Visiting clinical Professor of Pediatrics, University of California San Diego, Rady Children's Hospital, Professor Emeritus, University of Iowa, Iowa City, Iowa. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2019.01.006DOI Listing
January 2019
3 Reads

Effectiveness and safety of oral tacrolimus in refractory chronic urticaria.

J Allergy Clin Immunol Pract 2019 Jan 12. Epub 2019 Jan 12.

Department of Internal Medicine, Division of Allergy & Immunology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.12.023DOI Listing
January 2019
2 Reads

[Omalizumab for the treatment of chronic urticaria: Real-life findings].

Ann Dermatol Venereol 2019 Jan 9;146(1):9-18. Epub 2019 Jan 9.

Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Inserm U1135, Cimi-Paris, centre d'immunologie et de maladies infectieuses, 75013 Paris, France.

Objective: Assessment of the efficacy and safety of omalizumab in chronic urticaria refractory to conventional treatment (H1-antihistamines at high dosage and montelukast) in real-life practice.

Patients And Methods: A retrospective, descriptive, single-centre study was performed of the data for all patients presenting refractory chronic spontaneous urticaria or inducible urticaria and receiving omalizumab (300mg every four weeks) from November 2012 to June 2016.

Results: In all, 23 patients were included. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01519638183127
Publisher Site
http://dx.doi.org/10.1016/j.annder.2018.07.031DOI Listing
January 2019
5 Reads

Injection site reactions with the use of biological agents.

Dermatol Ther 2019 Jan 13:e12817. Epub 2019 Jan 13.

Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.

Injection site reactions (ISRs) are a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection. This article reviews the different aspects of ISRs, including their epidemiology and pathogenesis, and provides practical guidance to diagnose and treat such reactions. More focus is given to food and drug administration (FDA)-approved biological agents and biosimilars, which are licensed mainly for the treatment of dermatological conditions, including psoriasis, atopic dermatitis, and chronic urticaria. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/dth.12817
Publisher Site
http://dx.doi.org/10.1111/dth.12817DOI Listing
January 2019
5 Reads

Relationship between Chronic urticaria and autoimmune thyroid disease.

J Adv Pharm Technol Res 2018 Oct-Dec;9(4):158-161

Department of Endocrine, Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Hives is an erythematous and itchy disease that commonly affects the trunk and the organs. Acute urticaria is a common disease and affects about 10%-20% of the population during its lifetime. In patients with chronic urticaria, about 25%-30% of cases, antithyroid peroxidase (TPO) was detected and Hashimoto's disease was diagnosed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/japtr.JAPTR_342_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302681PMC
January 2019
1 Read

Do helminth infections underpin urban-rural differences in risk factors for allergy-related outcomes?

Clin Exp Allergy 2019 Jan 11. Epub 2019 Jan 11.

Immunomodulation and Vaccines Programme, (MRC/UVRI and LSHTM) Uganda Research Unit, Medical Research Council/Uganda Virus Research Institute, Entebbe, Uganda.

Background: It is proposed that helminth exposure protects against allergy-related disease, by mechanisms that include disconnecting risk factors (such as atopy) from effector responses.

Objective: We aimed to assess how helminth exposure influences rural-urban differences in risk factors for allergy-related outcomes in tropical low- and middle-income countries.

Methods: In cross-sectional surveys in Ugandan rural Schistosoma mansoni (Sm)-endemic islands, and in nearby mainland urban communities with lower helminth exposure, we assessed risk factors for atopy (allergen-specific skin prick test [SPT] reactivity and IgE [asIgE] sensitization) and clinical allergy-related outcomes (wheeze, urticaria, rhinitis and visible flexural dermatitis), and effect modification by Sm exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cea.13335DOI Listing
January 2019
13 Reads

C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level.

Exp Dermatol 2019 Jan 11. Epub 2019 Jan 11.

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.

Chronic spontaneous urticaria (CSU) is a frequent disorder with recurrent itchy wheals and/or angioedema, and nearly 35% patients respond poorly to non-sedating H1 antihistamine treatment. CRP gene encodes the C-reactive protein, which is involved in the pathogenesis of CSU. To investigate the impacts of CRP polymorphisms on the susceptibility and therapeutic efficacy in the South Han CSU patients, we enrolled 145 CSU patients in our study. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/exd.13874
Publisher Site
http://dx.doi.org/10.1111/exd.13874DOI Listing
January 2019
5 Reads
3.762 Impact Factor

Novel Mutation in a Patient With APLAID and Cutis Laxa.

Front Immunol 2018 14;9:2863. Epub 2018 Dec 14.

Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

The auto-inflammation and phospholipase Cγ2 (PLCγ2)-associated antibody deficiency and immune dysregulation (APLAID) syndrome is a rare primary immunodeficiency caused by a gain-of-function mutation S707Y in the gene previously described in two patients from one family. The APLAID patients presented with early-onset blistering skin lesions, posterior uveitis, inflammatory bowel disease (IBD) and recurrent sinopulmonary infections caused by a humoral defect, but lacked circulating autoantibodies and had no cold-induced urticaria, contrary to the patients with the related PLAID syndrome. We describe a new APLAID patient who presented with vesiculopustular rash in the 1st weeks of life, followed by IBD, posterior uveitis, recurrent chest infections, interstitial pneumonitis, and also had sensorineural deafness and cutis laxa. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02863
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302768PMC
December 2018
6 Reads

The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in Chronic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.

Front Pharmacol 2018 18;9:1474. Epub 2018 Dec 18.

Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Chronic urticaria is a bothersome skin disease, and Chinese herbal medicine (CHM) is commonly used as adjuvant therapy. This study aimed to evaluate the effectiveness and safety of the mixture of two CHM formula, Xiao-Feng-San (XFS) and Qing-Shang-Fang-Feng-Tang (QSFFT), in treating urticaria through a randomized, double-blind, placebo-controlled clinical trial. 78 participants entered the screening phase between November 2012 and August 2015. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fphar.2018.01474
Publisher Site
http://dx.doi.org/10.3389/fphar.2018.01474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305335PMC
December 2018
10 Reads

Higher Levels of Depression and Anxiety in Patients with Chronic Urticaria.

Authors:
Tugba Songul Tat

Med Sci Monit 2019 Jan 4;25:115-120. Epub 2019 Jan 4.

Allergy and Immunology Unit, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey.

BACKGROUND Chronic urticaria (CU) is a common disease, characterized by the development of wheals, angioedema, or both. CU reduces quality of life and can also cause emotional distress. Studies addressing depression and anxiety in such patients are rare in the literature. Read More

View Article

Download full-text PDF

Source
https://www.medscimonit.com/abstract/index/idArt/912362
Publisher Site
http://dx.doi.org/10.12659/MSM.912362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329254PMC
January 2019
4 Reads

Humanistic Burden of Refractory and Nonrefractory Chronic Idiopathic Urticaria: A Real-World Study in the United States.

Clin Ther 2018 Dec 31. Epub 2018 Dec 31.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address:

Purpose: Chronic idiopathic urticaria (CIU) is a debilitating skin condition that can profoundly affect patients' quality of life. This study explored the impact of refractory and nonrefractory CIU on patients in the real-world setting in the United States.

Methods: Data were collected from the Adelphi Real World 2015 Urticaria Disease-Specific Programme. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2018.12.004DOI Listing
December 2018
3 Reads

[Metabolic syndrome and chronic urticaria].

Rev Alerg Mex 2018 Oct-Dec;65(4):422-423

Universidad de Especialidades Espíritu Santo, Escuela de Medicina, Samborondón, Ecuador.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.29262/ram.v65i4.554DOI Listing
January 2019
1 Read

Role of Atorvastatin in Treatment of Chronic Spontaneous Urticaria Patients: A Controlled Clinical Trial.

Egypt J Immunol 2018 Jun;25(2):133-139

Department of Microbiology & Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Chronic spontaneous urticaria (CSU) is a popular disease, affects patients' life. Its etiologic agents are not well known so; treatment of the patients is difficult. CD203c is a marker that is only present on basophils. Read More

View Article

Download full-text PDF

Source
June 2018
1 Read

Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.

Allergy 2018 Dec 28. Epub 2018 Dec 28.

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/all.13714DOI Listing
December 2018
4 Reads

Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria.

J Immunol Res 2018 21;2018:5615109. Epub 2018 Nov 21.

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Chronic spontaneous urticaria (CSU) is defined by the appearance of wheals and a variable presence of angioedema which persists for at least 6 weeks. It represents the most common subtype of chronic urticaria and is gaining importance in civil society because of its association with impaired quality of life. Moreover, CSU has a growing impact on national health systems representing a great burden due to its variable rate of response to the approved therapies. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/jir/2018/5615109/
Publisher Site
http://dx.doi.org/10.1155/2018/5615109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280255PMC
November 2018
6 Reads

Review of cold-induced urticaria characteristics, diagnosis and management in a Western Canadian allergy practice.

Allergy Asthma Clin Immunol 2018 18;14:85. Epub 2018 Dec 18.

2Division of Allergy and Immunology, University of British Columbia, Suite 207 - 3195 Granville Street, Vancouver, BC V5R 3V8 Canada.

Background: Cold-induced urticaria is a significant condition, especially among young females. Despite the morbidity of this disease, studies that fully characterize the disease are limited.

Methods: We analyzed the characteristics of patients diagnosed with cold-induced urticaria at a community-based allergy practice in Vancouver, BC, Canada between 2003 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13223-018-0310-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299577PMC
December 2018
3 Reads

Association between dry eye disease and asthma: a nationwide population-based study.

PeerJ 2018 5;6:e5941. Epub 2018 Dec 5.

Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

Background: Dry eye disease (DED), a chronic ocular disease, is associated with numerous medical issues, including asthma. However, studies on these associations are limited. In this study, we investigated the incidence of DED among patients with asthma and its correlation with other allergic comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7717/peerj.5941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286656PMC
December 2018
1 Read

Angioedema of the small bowel caused by lisinopril.

Drug Ther Bull 2019 Jan;57(1):14-15

Gastroenterology, McLaren of Greater Lansing, Lansing,, Michigan, United States of America.

In conjunction with , will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/dtb.2018.225396repDOI Listing
January 2019
3 Reads